1007.3500 11.25 (1.13%)
NSE Sep 03, 2025 09:34 AM
Volume: 114.9K
 

1007.35
1.13%
Sharekhan
Revenue amounted to Rs. 5,237 crore, reflecting a 20% y-o-y increase but a 16% q-o-q decline,
primarily driven by reduced performance in the Indian consumer wellness segment, US
formulations and API business.
Deven Choksey increased Buy price target of Zydus Lifesciences Ltd. to 1183.0 on 25 Aug, 2025.
More from Zydus Lifesciences Ltd.
Recommended